Drug intelligence / Profile preview

COMP03

Development stage: Preclinical
Lead developer: Promius Pharma, LLC

Overview

COMP03 is an investigational drug being developed by Promius Pharma, LLC. It is currently under evaluation in clinical trials for the treatment of facial and/or scalp keratosis. The drug is being studied both as a standalone treatment and in combination with ACT01, as well as other compounds (Comp01, Comp02, Comp04). Further details regarding its mechanism of action, specific formulation, and development phase are not publicly available at this time.

Beyond the preview

Go deeper on COMP03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COMP03.

Explore the full profile